TG Therapeutics, Inc. reported third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million. They raised their full year 2025 global revenue target to $600 million and full year BRIUMVI U.S. net revenue target to approximately $585 million. The company also announced a conference call for November 3, 2025.

The company’s Chairman and CEO, Michael S. Weiss, highlighted strong performance in the third quarter, with 84% growth in BRIUMVI U.S. net product revenue. They are focusing on expanding patient awareness, advancing clinical trials, and driving growth. TG Therapeutics also completed a $100 million share repurchase program and authorized an additional $100 million program.

Recent developments include BRIUMVI commercialization expansion outside the U.S., successful completion of Phase 3 programs, and enrollment in ongoing clinical trials. Data presentations at the 2025 ECTRIMS meeting showed positive outcomes for patients with RMS on continuous BRIUMVI treatment.

Financially, product revenue, net totaled $159.3 million in the third quarter of 2025, with BRIUMVI U.S. net product sales at $152.9 million. Total global revenue target for 2025 was raised to approximately $600 million. R&D expenses increased due to manufacturing and development costs, while SG&A expenses also rose. TG Therapeutics reported an increase in selling, general, and administrative costs for the three and nine months ending September 30, 2025, due to marketing and personnel expenses. Net income for the same periods was $390.9 million and $424.1 million, respectively. Cash position as of September 30, 2025, was $178.3 million. A non-recurring tax benefit of $365.0 million was included in the third quarter results.

BRIUMVI, a novel monoclonal antibody targeting CD20-expressing B-cells, is indicated for the treatment of adults with RMS. The drug is designed to efficiently deplete B-cells at low doses. BRIUMVI is contraindicated in patients with active Hepatitis B Virus infection or a history of life-threatening infusion reactions. Common side effects include infusion reactions and infections.

Patients treated with BRIUMVI may experience infusion reactions, with 0.6% being serious. Serious, life-threatening infections have been reported in patients, with a 5% rate of serious infections. Patients should be screened for Hepatitis B Virus before treatment. Progressive Multifocal Leukoencephalopathy (PML) has been observed in patients treated with other anti-CD20 antibodies.

It is recommended to administer all immunizations according to guidelines, with live vaccines given at least 4 weeks prior to BRIUMVI initiation. If PML is suspected, BRIUMVI should be withheld and appropriate diagnostic evaluations performed. Treatment with BRIUMVI should be discontinued if PML is confirmed. The safety of immunization with live or live-attenuated vaccines during BRIUMVI treatment is not recommended. Vaccination of infants born to mothers treated with BRIUMVI during pregnancy should be carefully assessed due to potential risks from live vaccines. BRIUMVI may cause fetal harm and lead to decreased immunoglobulin levels and liver injury.

Liver injury, without viral hepatitis findings, has been reported in patients treated with anti-CD20 B-cell depleting therapies like BRIUMVI. Patients with significantly elevated liver enzymes and bilirubin levels are potentially at risk for severe liver injury. Monitoring liver function and promptly addressing symptoms of liver injury is important during BRIUMVI treatment.

The most common adverse reactions to BRIUMVI in RMS trials were infusion reactions and upper respiratory tract infections. Patients, physicians, and healthcare professionals seeking more information about BRIUMVI can visit the official website. TG Therapeutics offers a patient support program designed to assist U.S. patients through their treatment journey.

TG Therapeutics is a biopharmaceutical company focused on treatments for B-cell diseases. BRIUMVI is approved for the treatment of adult patients with relapsing forms of multiple sclerosis. Multiple sclerosis is a chronic demyelinating disease of the central nervous system, affecting nearly 1 million people in the U.S. and over 2.3 million worldwide.

This press release contains forward-looking statements regarding TG Therapeutics’ future operations and financial position. Caution is advised as actual events or results may differ from those expressed or implied. Risks, uncertainties, and important factors may impact the accuracy of these forward-looking statements. Visit TG Therapeutics’ official website for more information. TG Therapeutics, Inc. released factors that could affect actual results, including the commercialization of BRIUMVI® for RMS, revenue targets, clinical trials, and regulatory approvals. Risks include prescription trends, payor coverage, and meeting post-approval obligations. Financial data for the third quarter of 2025 showed significant revenue growth and operating profit. Net income per common share also increased.

TG Therapeutics, Inc. reported revenue of $161.7 million in the third quarter of 2025, up from $83.9 million in the same period last year. Total revenue for nine months ended September 30, 2025, was $423.7 million compared to $220.8 million in 2024. Operating profit increased to $29.4 million. Net income for the quarter was $390.9 million.

TG Therapeutics, Inc. outlined risks to commercializing BRIUMVI, including maintaining prescription trends, obtaining payor coverage, and post-approval obligations. Financial data for the third quarter of 2025 showed significant revenue growth, operating profit, and net income per common share. Total revenue for nine months ended September 30, 2025, was $423.7 million. 1. The stock market experienced a significant drop today, with the S&P 500 falling 2.1% and the Dow Jones Industrial Average losing 600 points. This decline was attributed to concerns about rising inflation and its impact on the economy.

2. In other news, a new study found that 75% of Americans are now fully vaccinated against COVID-19. This is a major milestone in the fight against the pandemic, but experts warn that continued vigilance is needed to prevent future outbreaks.

3. The United Nations released a report stating that global temperatures are on track to rise by 2.7 degrees Celsius by the end of the century. This alarming trend highlights the urgent need for countries to take action to reduce greenhouse gas emissions and combat climate change.

Read more at GlobeNewswire.

1. Tesla surpasses $1 trillion market value, becoming one of the world’s most valuable companies. The electric vehicle maker’s stock price rose 3.1% to reach a new all-time high. Tesla’s market cap now exceeds that of major tech giants like Apple and Microsoft.

2. The United States adds 943,000 jobs in July, beating expectations and marking the biggest gain in nearly a year. The unemployment rate falls to 5.4%, signaling a strong rebound in the labor market post-pandemic. Job gains were seen across various sectors, including leisure and hospitality.

3. Pfizer and Moderna raise vaccine prices in the latest EU contracts. The price hike comes as the companies negotiate new deals with the European Union for COVID-19 vaccines. Pfizer’s vaccine price increased by 25% while Moderna’s rose by 10%, according to sources familiar with the matter.: TG Therapeutics Reports Third Quarter 2025 Financial